GlassScriptPhysician profile
Randall R Ingham
NPI 1215257027
$99,526.26
in general payments reported to CMS, 2019-2025
13 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $11K · 2021: $16K · 2022: $3,153 · 2023: $12K · 2024: $6,980 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Food and Beverage: $419 · Travel and Lodging: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,270.00 |
| Food and Beverage | $419.14 |
| Travel and Lodging | $332.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $59,811.74 | 2019-2024 | Tecentriq |
| Astrazeneca Pharmaceuticals LP | $22,102.47 | 2021-2025 | Lynparza, Tagrisso, Imfinzi |
| Jazz Pharmaceuticals INC. | $7,980.00 | 2020-2021 | |
| Abbvie INC. | $5,852.13 | 2020-2023 | |
| Beigene USA, INC. | $1,650.00 | 2023 | Brukinsa |
| Glaxosmithkline, LLC. | $975.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $890.00 | 2025 | |
| Stemline Therapeutics INC. | $151.59 | 2023-2024 | Orserdu |
| Caris Mpi, INC. | $41.72 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $20.93 | 2025 | |
| Exelixis INC. | $19.18 | 2025 | Cabometyx |
| Astellas Pharma Global Development | $17.89 | 2025 | Vyloy |
| Array Biopharma INC | $13.61 | 2024 | Lorbrena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Ingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.